Tag: cas9

Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034: Visiongain

Visiongain Reports Ltd Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS…

Continue Reading Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034: Visiongain

Translational Regenerative Medicine market is estimated to

Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading…

Continue Reading Translational Regenerative Medicine market is estimated to

The woman behind the genomic scissors CRISPR-Cas9 :: Understanding Animal Research

For this year’s women and girls in science day, UAR chose to highlight the career of a world-renowned scientist and how animal research shaped her path to becoming one of the most respected and revered researchers. Working in fundamental science and microbiology, Emmanuelle Charpentier gradually obtained prizes, eventually receiving one…

Continue Reading The woman behind the genomic scissors CRISPR-Cas9 :: Understanding Animal Research

Functional genomic screening in Komagataella phaffii enabled by high-activity CRISPR-Cas9 library

Abstract CRISPR-based high-throughput genome-wide loss-of function screens are a valuable approach to functional genetics and strain engineering. The yeast Komagataella phaffii is a host of particular interest in the biopharmaceutical industry and as a metabolic engineering host for proteins and metabolites. Here, we design and validate a highly active 6-fold…

Continue Reading Functional genomic screening in Komagataella phaffii enabled by high-activity CRISPR-Cas9 library

CRISPR/Cas9 are the Most Sought Genome Editing Tools

Company Logo Global Genome Editing Market Global Genome Editing Market Dublin, Feb. 09, 2024 (GLOBE NEWSWIRE) — The “Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts” report has been added to ResearchAndMarkets.com‘s offering. The global genome editing market size for technologies is estimated to be worth…

Continue Reading CRISPR/Cas9 are the Most Sought Genome Editing Tools

All Roads Lead to Genome Editing

Shondra Pruett-Miller, a biochemist at St. Jude Children’s Research Hospital, found her calling during her first year of graduate school at the University of Texas, Southwestern. In 2003, during the departmental faculty research talks, she watched with excitement as Matthew Porteus, now a biochemist at Stanford University, presented his research…

Continue Reading All Roads Lead to Genome Editing

How the Quantum World Can Help Scientists Engineer Biology

The Science Newswise — CRISPR-Cas is a tool that allows scientists to make targeted changes to an organism’s DNA. This tool consists of two parts. The first is a microscopic substance called a nuclease Cas protein (e.g., Cas9) that can cleave DNA. The second is an RNA molecule (also called…

Continue Reading How the Quantum World Can Help Scientists Engineer Biology

ZsGreen/Luciferase Safe-Harbor HEK293 Cell Line | BPS Bioscience

Product information “ZsGreen/Luciferase Safe-Harbor HEK293 Cell Line” Recombinant stable HEK293 cell line constitutively expressing ZsGreen (bright green fluorescent protein derived from Zoanthus sp. reef coral) and firefly luciferase, which have been stably integrated into the AAVS1 safe harbor locus on chromosome 19 using CRISPR/Cas9. Expression of ZsGreen and the luciferase…

Continue Reading ZsGreen/Luciferase Safe-Harbor HEK293 Cell Line | BPS Bioscience

Treating the Untreatable with Precision Therapies – A $4 trillion Opportunity?

Precision Therapies For Targeted Results Precision therapies have always been the ultimate goal of medicine. Instead of drugs acting on multiple parts of the body, these therapies would only target one organ, one cell, or even one gene. In theory, not only would this be a lot more efficient, but…

Continue Reading Treating the Untreatable with Precision Therapies – A $4 trillion Opportunity?

what will therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a declining cancer death rate – by 33% to be precise – since the…

Continue Reading what will therapy look like in 2034?

Twisted DNA Increases CRISPR Off-target Effects

At the end of 2023, the FDA approved Casgevy for sickle cell disease, its first approval for a therapeutic that used the genome editing tool clustered regulatory interspaced palindromic repeats (CRISPR) to specifically inactivate a human gene as a treatment for a genetic disease. While CRISPR-based gene therapies could potentially…

Continue Reading Twisted DNA Increases CRISPR Off-target Effects

Advancements in CRISPR-Based Pathogen Detection: Limitations and Recent Progress

Gene editing technologies, particularly those based on Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), have revolutionized our ability to accurately and swiftly detect pathogens. However, even these advanced methods have their limitations. This article explores these limitations and highlights recent advancements that are paving the way for faster, more accurate…

Continue Reading Advancements in CRISPR-Based Pathogen Detection: Limitations and Recent Progress

CRISPR Off-target Sequencing for Agriculture

CRISPR-Cas (clustered regularly interspaced short palindromic repeats-CRISPR-associated protein) genome editing enables precise, targeted genetic modification of plants. To date, the genomes of several crops, including rice, tomato, corn, wheat, soybean, barley, potato, sorghum, apple, grapefruit, and orange, have been edited using CRISPR-Cas-based genome editing technology. The CRISPR system cuts not…

Continue Reading CRISPR Off-target Sequencing for Agriculture

Two Million Cancers; Casgevy OK’d for Thalassemia; Rectal Exams and Prostate Cancer

While cancer mortality continues to decline, the number of new cases is projected to top 2 million in 2024, according to the American Cancer Society’s annual report on cancer statistics. The FDA approved exagamglogene autotemcel (Casgevy) for transfusion-dependent beta thalassemia in patients 12 years and older, maker Vertex announced. This…

Continue Reading Two Million Cancers; Casgevy OK’d for Thalassemia; Rectal Exams and Prostate Cancer

Path to Safer Genome Engineering: CRISPR Off-Switches?

Using CRISPR, an immune system bacteria use to protect themselves from viruses, scientists have harnessed the power to edit genetic information within cells. In fact, the first CRISPR-based therapeutic was recently approved by the FDA to treat sickle cell disease in December 2023. That therapy is based on a highly…

Continue Reading Path to Safer Genome Engineering: CRISPR Off-Switches?

Study of CRISPR-Cas3 brings us a step closer

 Cornell researchers have taken an important step toward harnessing CRISPR gene editing in “targeted, safe and potent” cancer treatment, according to Ailong Ke, professor of chemistry and chemical biology in the College of Arts and Sciences. The enzyme CRISPR-Cas3, one of many different CRISPR systems found naturally in the immune systems…

Continue Reading Study of CRISPR-Cas3 brings us a step closer

Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly

Capturing proteins associated with SARS-CoV-2 virions To identify host cell proteins potentially present in extracellular SARS-CoV-2 virions, viral particles were produced from two lung epithelial cell models, A549 cells overexpressing ACE2 receptor (A549-ACE2) and Calu-3 cells that naturally express ACE2 receptor and TMPRSS2. Following infection with the D614G SARS-CoV-2 strain32,…

Continue Reading Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly

The Role of Nanoparticles in Cancer Therapy: Advancements in Nanotechnology

With the advent and advancements in nanotechnology, the field of cancer therapy is witnessing a paradigm shift. Nanoparticles, owing to their unique properties, are proving to be promising carriers for drug delivery in cancer therapy. The study scrutinizes the transport of nanoparticles in two abnormal microenvironments through a 2-D simulation…

Continue Reading The Role of Nanoparticles in Cancer Therapy: Advancements in Nanotechnology

Week 7 Discussion (docx) – Course Sidekick

Option 2: Genetics is a rapidly evolving area of science. Each year, advances in genetics bring exciting new technologies to the market. Areas such as forensics, genealogy, and healthcare have all been affected by new genetic technologies. Choose a genetic technology and report on how this technology is affecting or…

Continue Reading Week 7 Discussion (docx) – Course Sidekick

CRISPR off-switches: A path towards safer gen

Using CRISPR, an immune system bacteria use to protect themselves from viruses, scientists have harnessed the power to edit genetic information within cells. In fact, the first CRISPR-based therapeutic was recently approved by the FDA to treat sickle cell disease in December 2023. That therapy is based on a highly…

Continue Reading CRISPR off-switches: A path towards safer gen

could it be a cure?

When CASGEVY, the first CRISPR-based therapy, was approved by the FDA in December, it gave CRISPR technology the validation it needed. Any promise it had held before that moment was simply investigational. In this case, the approval of CASGEVY was granted for the treatment of two blood disorders – sickle…

Continue Reading could it be a cure?

Genetic Frontiers: Ethical Dilemmas in the Age of CRISPR | by Amy Belluomini | Jan, 2024

Photo by Sangharsh Lohakare on Unsplash In the landscape of scientific advancement, the emergence of CRISPR technology has propelled humanity into a new era of genetic possibilities. While the revolutionary gene-editing tool offers unprecedented opportunities to reshape the blueprint of life, it also raises profound ethical dilemmas that echo through…

Continue Reading Genetic Frontiers: Ethical Dilemmas in the Age of CRISPR | by Amy Belluomini | Jan, 2024

miR-195b is required for proper cellular homeostasis in the elderly

Expression pattern of miR-195 during embryonic development We analyzed the expression pattern of miR-195 by in situ hybridization at two distinct developmental stages in mouse embryos. Whole-mount in situ hybridization at E10.5, demonstrated a wide expression of miR-195 along the entire embryo, including the central nervous system, the cardiopharyngeal area,…

Continue Reading miR-195b is required for proper cellular homeostasis in the elderly

2 low-priced gene therapy stocks to speculate on

Key Points bluebird bio has three FDA-approved gene therapy treatments that are planning to commercialize after its $150 million secondary offering of common shares priced at $1.50 per share. bluebird bio’s latest FDA approval, LYFGENIA, is a one-time treatment for sickle cell disease, which is priced around $3.1 million per…

Continue Reading 2 low-priced gene therapy stocks to speculate on

Sox2 Gene Enhancers: Unraveling Cancer’s Genetic Secrets

Unveiling Cancer’s Genetic Mechanisms: Role of Sox2 Gene Enhancers In a groundbreaking study led by Professor Jennifer Mitchell at the University of Toronto’s Department of Cell and Systems Biology, vital insights were garnered on the role of ‘enhancer’ regions in gene expression and their implications for cancer growth. Enhancers, non-coding…

Continue Reading Sox2 Gene Enhancers: Unraveling Cancer’s Genetic Secrets

Global Genome Editing Market Exhibits Robust Growth Amid Therapeutic Advances And Agricultural Biotechnology Expansion

(MENAFN– PR Newswire) DUBLIN, Jan. 8, 2024 /PRNewswire/ — The “Genome Editing Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F” report has been added to ResearchAndMarkets’s offering. The transformative power of genome editing continues to spur significant growth in the biotechnology sector, with the Global Genome Editing…

Continue Reading Global Genome Editing Market Exhibits Robust Growth Amid Therapeutic Advances And Agricultural Biotechnology Expansion

CRISPR Therapeutics Highlights Strategic Priorities and

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth. “We had a landmark year in 2023, marked…

Continue Reading CRISPR Therapeutics Highlights Strategic Priorities and

The best countries for biotech according to the OECD

The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech companies (2,840) and an R&D intensity added value of 17%, the U.S. remains a strong leader in the industry. But…

Continue Reading The best countries for biotech according to the OECD

Crispr Library Download

CRISPR guide RNA libraries have been iteratively improved to provide increasingly efficient reagents, although their large size is a barrier for many applications. We design an optimised minimal genome-wide human CRISPR-Cas9 library (MinLibCas9) by mining existing large-scale gene loss-of-function datasets, resulting in a greater than 42% reduction in size compared…

Continue Reading Crispr Library Download

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) market 2023-2030

Market Overview The Middle East and Africa (MEA) region is witnessing significant advancements in the field of regenerative medicine, particularly in the area of induced pluripotent stem cells (iPSCs). iPSCs are derived from adult cells and possess the remarkable ability to differentiate into various cell types, making them a valuable…

Continue Reading Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) market 2023-2030

Biophysical Society names fellows

Rommie Amaro Ivet Bahar Jennifer Doudna The Biophysical Society has named seven 2024 society fellows, and three of them are members of the American Society for Biochemistry and Molecular Biology: Rommie Amaro, Ivet Bahar and Jennifer Doudna. Amaro is a professor and endowed chair in the molecular biology department and…

Continue Reading Biophysical Society names fellows

Science and technology trends that defined 2023

The year 2023 has been marked by significant advancements and breakthroughs in science and technology. From AI and quantum computing to genomic medicine and renewable energy, emerging technologies have reshaped various industries. With trends like the metaverse and advancements in space exploration, the future looks promising for continued progress and…

Continue Reading Science and technology trends that defined 2023

Knockout of lipoprotein lipase with CRISPR/Cas9 causes severe developmental defects and affects lipid deposition in Japanese medaka (Oryzias latipes)

Abstract In mammals, lipoprotein lipase (LPL) has been found to play an important role in lipid mentalism and deposition. LPL deficiency in humans (Homo sapiens) and mice (Mus musculus) tends to cause hypertriglyceridemia. The lpl gene is not expressed in adult mammalian liver, but is in adult fish liver. The…

Continue Reading Knockout of lipoprotein lipase with CRISPR/Cas9 causes severe developmental defects and affects lipid deposition in Japanese medaka (Oryzias latipes)

Low dose ribosomal DNA P-loop mutation affects development and enforces autophagy in Arabidopsis

Arabidopsis contains hundreds of ribosomal DNA copies organized within the nucleolar organizing regions (NORs) in chromosomes 2 and 4. There are four major types of variants of rDNA, VAR1–4, based on the polymorphisms of 3’ external transcribed sequences. The variants are known to be differentially expressed during plant development. We…

Continue Reading Low dose ribosomal DNA P-loop mutation affects development and enforces autophagy in Arabidopsis

Pharmaceutics | Free Full-Text | Natural Biopolymer-Based Delivery of CRISPR/Cas9 for Cancer Treatment

Cancer is one of the leading causes of disease-associated mortality, with a rising incidence worldwide [1]. Although many therapeutic methods have been used in cancer treatment, such as chemotherapy, radiotherapy, surgery, and targeted therapy, the overall therapeutic outcome remains unsatisfactory. Therefore, developing new therapeutic means is urgently needed. With advances…

Continue Reading Pharmaceutics | Free Full-Text | Natural Biopolymer-Based Delivery of CRISPR/Cas9 for Cancer Treatment

Top Biology Professor In Israel For Solidarity Visit

Prof. Eugene Koonin, one of the world’s leading evolutionary biologists, recently visited Israel as a gesture of solidarity and even took the time to volunteer in the Gaza border communities that came under attack on October 7.   Koonin is among the scientists who discovered the CRISPR mechanism, the hallmark…

Continue Reading Top Biology Professor In Israel For Solidarity Visit

FDA approves two gene therapy treatments for sickle cell disease

Two new gene therapies to treat sickle cell disease were approved by the U.S. Food and Drug Administration Dec. 8. The treatments, both produced by Boston-area companies, join 32 other approved gene therapies and are approved to treat the disease in the United States. Experts say the developments are a…

Continue Reading FDA approves two gene therapy treatments for sickle cell disease

MAVS found to antagonize human stem cell senescence as a mitochondrial stabilizer

MAVS maintains mitochondrial homeostasis and regulates cellular senescence through stabilizing OPA1. A. Depletion of MAVS accelerates cellular senescence of human mesenchymal stem cells. B. MAVS deficiency compromises mitochondrial dynamics. C. A model illustrating the MAVS-OPA1 axis regulates mitochondrial homeostasis and human stem cell senescence. Credit: Research A recent study led…

Continue Reading MAVS found to antagonize human stem cell senescence as a mitochondrial stabilizer

csi-miR-96-5p delivered by Clonorchis sinensis extracellular vesicles promotes intrahepatic cholangiocarcinoma proliferation and migration via the ferroptosis-related PTEN/SLC7A11/GPX4 axis | Parasites & Vectors

Human tissue samples The preoperative diagnosis of CS mainly relies on stool microscopy, enzyme-linked immunosorbent assay, or endoscopy. Fresh liver and intrahepatic bile duct specimens were collected from ICC patients with (CS-ICC group) and without (NC-ICC group) CS infection during partial hepatectomy at the First Hospital of Jilin University. Tumor tissues…

Continue Reading csi-miR-96-5p delivered by Clonorchis sinensis extracellular vesicles promotes intrahepatic cholangiocarcinoma proliferation and migration via the ferroptosis-related PTEN/SLC7A11/GPX4 axis | Parasites & Vectors

Summary of Genomics and Transcriptomics – DNA sequencing I. Goal II. Methodology A. Sanger DNA

DNA sequencing I. Goal II. Methodology A. Sanger DNA sequencing ● Up to 900 base pairs ● Primer extension with labeled ddNTPs (radioactive or fluorescent) ● Prior knowledge on target needed ● Difficult to detect variation in mixtures ● High accuracy + still in use for genotyping When it is…

Continue Reading Summary of Genomics and Transcriptomics – DNA sequencing I. Goal II. Methodology A. Sanger DNA

Charles River’s (CRL) Memphis Site Achieves Crucial Approval

Charles River Laboratories International, Inc. CRL recently achieved an important milestone in its strategic collaboration with Vertex Pharmaceuticals to manufacture CASGEVY (exagamglogene autotemcel [exa-cel]). The company’s Memphis facility has been approved to manufacture Vertex’s CASGEVY — the first-ever gene-edited therapy in the world that targets severe sickle cell disease (SCD)….

Continue Reading Charles River’s (CRL) Memphis Site Achieves Crucial Approval

K-State researchers lower gluten content, maintain dough quality in wheat bread

MANHATTAN, Kan. (WIBW) – Kansas State University researchers have recently discovered ways to keep those with gluten allergies safer. Researchers have reported a breakthrough in developing wheat-based foods that contain lower amounts of gluten, a discovery that may lessen the adverse effects for those with celiac or other autoimmune diseases….

Continue Reading K-State researchers lower gluten content, maintain dough quality in wheat bread

Biotechnology Breakthroughs: How Genetic Engineering is Revolutionizing Healthcare

Share Tweet Share Share Email Among the various branches of biotechnology, genetic engineering stands out as a revolutionary field that holds immense potential for transforming healthcare as we know it. This article explores the latest biotechnological breakthroughs, focusing on how genetic engineering is…

Continue Reading Biotechnology Breakthroughs: How Genetic Engineering is Revolutionizing Healthcare

The Next Chapter in Genome Editing? Tome Emerges from Stealth with $213M

Rahul Kakkar, MD, Tome Biosciences president and CEO While the CRISPR community celebrates the recent first FDA approval of a CRISPR-Cas9 therapy (Casgevy), new entities are making strides in their efforts to write perhaps the definitive new chapter in programmable genome editing. Last week, Tome Biosciences—a developer of genome editing…

Continue Reading The Next Chapter in Genome Editing? Tome Emerges from Stealth with $213M

CRISPR/Cas9-mediated nexilin deficiency interferes with cardiac contractile function in zebrafish in vivo

CRISPR/Cas9-induced homozygous knockout of nexn causes progressive cardiac dysfunction without affecting skeletal muscle function in zebrafish Several studies in different animal models and cardiomyopathy patients have shown that loss of NEXN is leading to DCM which is characterized by an impaired contractility of the heart6,10,12. Homozygous loss of NEXN mostly…

Continue Reading CRISPR/Cas9-mediated nexilin deficiency interferes with cardiac contractile function in zebrafish in vivo

Better Growth Stock: Archer Aviation or Prime Medicine? , The Motley Fool

Small-cap stocks are often attractive investments in bullish markets. While a bull market in 2024 is not guaranteed, some small caps are already warming up in anticipation of better economic conditions next year. As a result, it may be a smart move to start adding some select small caps to…

Continue Reading Better Growth Stock: Archer Aviation or Prime Medicine? , The Motley Fool

Viral Vectors and Plasmid DNA Manufacturing market is

Visiongain has published a new report entitled Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034: Forecasts by Vector Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), by Application (Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology), by End-use (Pharma and Biopharma Companies, Research Institutes), by Disease (Oncology, Genetic Disorders,…

Continue Reading Viral Vectors and Plasmid DNA Manufacturing market is

Casgevy, sickle cell gene-editing therapy, favored for EU approval

A European Medicines Agency committee has issued a positive opinion on the gene-editing therapy Casgevy (exagamglogene autotemcel) in treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The Committee for Medicinal Products for Human Use (CHMP) recommendation will be considered by the European Commission in making a final approval decision…

Continue Reading Casgevy, sickle cell gene-editing therapy, favored for EU approval

Tome Biosciences CEO Rahul Kakkar on recent funding round

Tome Biosciences made a splash last week when it emerged from stealth mode with $213 million in funding. The programmable genomic integration (PGI) company based in Watertown, Massachusetts, raised significant financing from investors like Andreessen Horowitz (a16z) Bio + Health, Arch Venture Partners, Fujifilm Corporation and others.  Tome CEO Rahul Kakkar, MD…

Continue Reading Tome Biosciences CEO Rahul Kakkar on recent funding round

HUIADGENE ANNOUNCES RARE PEDIATRIC DRUG DESIGNATION GRANTED TO HG302, A NOVEL CRISPR DNA-EDITING THERAPY, FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

HG302 effectively generates stable genome editing with minimal off-target effects in-vitro and in-vivo A single intravenous injection of HG302 restores functional dystrophin protein expression HG302 demonstrates therapeutic effects by improving muscle functions in humanized DMD mice SHANGHAI and CLINTON, N.J., Dec. 19, 2023 /PRNewswire/ — HuidaGene Therapeutics (辉大基因”HuidaGene”) today announced…

Continue Reading HUIADGENE ANNOUNCES RARE PEDIATRIC DRUG DESIGNATION GRANTED TO HG302, A NOVEL CRISPR DNA-EDITING THERAPY, FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Solved 33. The coding DNA sequence of a human gene contains

Transcribed image text: 33. The coding DNA sequence of a human gene contains 2001 base pairs. A CRISPR-Cas9 experiment is setting up to knock out this gene in the fibroblast cell lines. It is known that the GC content of the coding sequence of this gene is 60%. In CRISPR-Cas…

Continue Reading Solved 33. The coding DNA sequence of a human gene contains

FDA approved treatments use gene therapy to help patients with sickle cell disease

By Olivia Trani  The U.S. Food and Drug Administration recently approved two gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease in people ages 12 and older. One of the therapies, Casgevy, use a novel gene-editing technique called CRISPR/Cas9, which can modify a cell’s DNA at a targeted location…

Continue Reading FDA approved treatments use gene therapy to help patients with sickle cell disease

Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy

Vertex Pharmaceuticals Incorporated VRTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (“EMA”) had adopted a positive opinion, recommending the conditional approval of Casgevy to treat severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The CHMP’s recommendation, although not legally binding, will…

Continue Reading Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy

3 Biotech Stocks Most Wall Street Analysts Are Bullish About

The scenario for the biotech industry in 2024 looks upbeat after a challenging ride in 2023. New drug approvals, pipeline development, and an increase in mergers & acquisitions (M&A) activity boosted investor sentiment in the last couple of months, even though an uncertain macroeconomic environment was a headwind. Pharma and…

Continue Reading 3 Biotech Stocks Most Wall Street Analysts Are Bullish About

Global Oligonucleotide Library Market Research Report 2024-2031 | 117 Pages Report

(MENAFN– The Express Wire) Global |117 Pages| Report on “Oligonucleotide Library Market” offers a detailed analysis (2024-2031)which is expected to witness remarkable growth in the coming years. The implementation of new technologies and innovative solutions will drive the market’s revenue generation and increase its market share by 2031 with Revenue…

Continue Reading Global Oligonucleotide Library Market Research Report 2024-2031 | 117 Pages Report

Promising Biotech Selling Way Under Cash Value

Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater. We did very well with Talaris as a takeover…

Continue Reading Promising Biotech Selling Way Under Cash Value

Programmable Genomic Integration Company Raises Over $200 Million

Tome Biosciences – a programmable genomic integration company – recently announced it has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI). PGI enables the insertion of any DNA sequence of any size into any programmed genomic location. And the company has raised…

Continue Reading Programmable Genomic Integration Company Raises Over $200 Million

Charles River, Vertex Reach Milestone In Cell Therapy Collaboration

Charles River Laboratories reached a milestone in its strategic collaboration to manufacture CASGEVY (exagamglogene autotemcel [exa-cel]). CASGEVY has been approved in some countries for certain eligible patients. The news follows Charles River’s Memphis center of excellence passing back-to-back audits from both the U.S. FDA and the Health Products Regulatory Authority, on…

Continue Reading Charles River, Vertex Reach Milestone In Cell Therapy Collaboration

Genetic Engineering in Agriculture: Transforming the Future of Farming

In recent years, the field of genetic engineering in agriculture has been rapidly advancing, offering innovative solutions to some of the most pressing challenges in food production. As we look ahead to the period from 2023 to 2030, the global genetic engineering in agriculture market is poised to undergo significant…

Continue Reading Genetic Engineering in Agriculture: Transforming the Future of Farming

Scientists construct a synthetic yeast genome

The yeast genome contains redesigned chromosome sequences that can shed light on the impact of genetic variations on individual traits and potentially be used to reveal the causes of genetic diseases. Chromosomes are long DNA molecules that collectively form a genome, containing all the genetic material of an organism. Advances…

Continue Reading Scientists construct a synthetic yeast genome

CRISPR-Cas9 Gene Editing Service Market Size, Share Evaluate the Key Region Forecasted till 2024-2031

Global CRISPR-Cas9 Gene Editing Service Market” research and analysis play a crucial role in CRISPR-Cas9 Gene Editing Service Market strategies, as businesses seek to discover which CRISPR-Cas9 Gene Editing Services are most relevant and have the highest search volume within their niche. By understanding the CRISPR-Cas9 Gene Editing Service Market,…

Continue Reading CRISPR-Cas9 Gene Editing Service Market Size, Share Evaluate the Key Region Forecasted till 2024-2031

Discuss Cas9 Options | Aldevron

Aldevron complies with the requirements of the General Data Protection Regulation (GDPR). What We CollectInformation collected on this form will be used to contact you (by email or telephone) about your chosen areas of interest, or previous or proposed business transactions. How to withdraw your consentYou can choose whether or…

Continue Reading Discuss Cas9 Options | Aldevron

2 Stocks Profiting from Unstoppable Trends That Can Make You Rich The Motley Fool

Sometimes trends are short-term, and as a long-term investor, you probably won’t want to pay too much attention to them. But some trends, because of their potential to change the way things are done for the better, are worth a second look – and even investment. Today, both artificial intelligence…

Continue Reading 2 Stocks Profiting from Unstoppable Trends That Can Make You Rich The Motley Fool

Gene Editor to Treat Blood Diseases

The European Medicines Agency (EMA) has recommended granting conditional marketing authorization for Casgevy (exagamglogene autotemcel) for the treatment of transfusion-dependent beta-thalassemia and severe sickle cell disease in patients 12 years or older who are appropriate candidates for hematopoietic stem cell transplantation but a suitable donor is not available. The treatment…

Continue Reading Gene Editor to Treat Blood Diseases

CHMP recommends gene therapy for beta thalassemia and sickle cell disease

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel) to treat transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). SCD and beta thalassemia are genetic conditions caused by errors in the gene…

Continue Reading CHMP recommends gene therapy for beta thalassemia and sickle cell disease

Sickle cell triumph raises questions

In the realm of genetic manipulation, Crispr technology emerges as a double-edged sword. Enabling precise gene editing, it holds promise for eradicating diseases like sickle cell through treatments like Casgevy. Yet, with the power to shape the very fabric of life, ethical concerns loom large. While some foresee a future…

Continue Reading Sickle cell triumph raises questions

Vertex secures CHMP approval for Casgevy approval in Europe

Casgevy became first FDA-approved medicine to use CRISPR/Cas9 gene-editing technology. Image credit: Shutterstock/Nemes Laszlo. Vertex Pharmaceuticals has gained a positive opinion from the EMA’s CHMP for Casgevy (exa-cel), paving the way for European approval of the sickle cell gene therapy early next year. The CHMP will now send their recommendation…

Continue Reading Vertex secures CHMP approval for Casgevy approval in Europe

Researchers spotlight CRISPR-Cas systems for probiotic engineering

18 Dec 2023 — Researchers from Huazhong Agricultural University in China set out to promote the advancement of probiotic research by reviewing the latest advances and hurdles in CRISPR-Cas systems discovered in microorganisms. They propose a design route for CRISPR systems related to genetically engineered probiotics. While…

Continue Reading Researchers spotlight CRISPR-Cas systems for probiotic engineering

The Landscape of Agricultural Biotechnology

By 2049, our global population will reach ~9 billion people. Pests, diseases and adverse environmental conditions are impacting crops across the globe, compounding the issue of feeding a growing population. Traditional breeding techniques have enabled scientists and farmers to develop many varieties of plants and livestock tailored for specific agricultural…

Continue Reading The Landscape of Agricultural Biotechnology

CRISPR’s CRISPR Problem: Too Many Variants to Choose From | by AI Tools Finder | Dec, 2023

Scientists Use AI to Discover New CRISPR Systems CRISPR is a gene editing tool that has revolutionized the way scientists study and treat diseases. But there are still many unknowns about CRISPR, and scientists are constantly searching for new and improved ways to use it. A team of scientists at…

Continue Reading CRISPR’s CRISPR Problem: Too Many Variants to Choose From | by AI Tools Finder | Dec, 2023

Dawn of a Health Revolution: The Coming Breakthroughs Poised to Transform Medicine | by Dr Axel Coach | Dec, 2023

[High-concept in Medicine] The Latest Research in Medicine Photo by National Cancer Institute on Unsplash The future is rushing toward us with dizzying speed, bearing dazzling innovations that promise to reshape the landscape of medicine. Genetic diseases erased with the flick of a molecular scalpel; custom-grown organs fresh off the…

Continue Reading Dawn of a Health Revolution: The Coming Breakthroughs Poised to Transform Medicine | by Dr Axel Coach | Dec, 2023

US CRISPR Cas9 clearance; Lenovo looks to UK courts; video streaming secondary patent market; Nokia challenging Chinese ruling; WiFi 6 wars; plus much more

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week. MONDAY 11 December First US CRISPR Cas9 approval marks start of new era of patent wars Data…

Continue Reading US CRISPR Cas9 clearance; Lenovo looks to UK courts; video streaming secondary patent market; Nokia challenging Chinese ruling; WiFi 6 wars; plus much more

Study finds revolutionary cancer vaccine simultaneously kills and prevents brain cancer

[Dec. 17, 2023: JJ Shavit, The Brighter Side of News] Dual action cell therapy is engineered to eliminate established tumors and train the immune system to eliminate the primary tumor and prevent cancer recurrence. (Credit: Creative Commons) In a bold effort to rewrite the story of cancer treatment, scientists are…

Continue Reading Study finds revolutionary cancer vaccine simultaneously kills and prevents brain cancer

Biomedicines | Free Full-Text | Advances of Genome Editing with CRISPR/Cas9 in Neurodegeneration: The Right Path towards Therapy

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of…

Continue Reading Biomedicines | Free Full-Text | Advances of Genome Editing with CRISPR/Cas9 in Neurodegeneration: The Right Path towards Therapy

CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?

On Dec. 8, CRISPR Therapeutics (CRSP -1.37%) and its collaboration partner Vertex Pharmaceuticals (VRTX 1.00%) made history when the Food and Drug Administration (FDA) gave them the green light to commercialize their gene therapy for sickle cell disease (SCD), which is the first medicine to use the much vaunted CRISPR-Cas9…

Continue Reading CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?

CRISPR therapeutics made history. So why did its stock fall?

Related investors with two people in the background On 8th December, CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partners Vertex Pharmaceuticals (NASDAQ:VRTX) made history when the Food and Drug Administration (FDA) gave them the green light to commercialize their gene therapy for sickle cell disease (SCD) using the much-hyped CRISPR-Cas9…

Continue Reading CRISPR therapeutics made history. So why did its stock fall?

Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

(RTTNews) – Vertex Pharmaceuticals Inc. (VRTX) announced Friday that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and…

Continue Reading Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Improving recombinant protein production in CHO cells using the CRISPR-Cas system

Kalkan, Ali Kerem; Palaz, Fahreddin; Sofija, Semeniuk; Elmousa, Nada; Ledezma, Yuri; Cachat, Elise; Rios-Solis, Leonardo; (2023) Improving recombinant protein production in CHO cells using the CRISPR-Cas system. Biotechnology Advances , 64 , Article 108115. 10.1016/j.biotechadv.2023.108115. Text Improving recombinant protein production in CHO cells using the CRISPR-Cas system.pdf – Accepted Version…

Continue Reading Improving recombinant protein production in CHO cells using the CRISPR-Cas system

FDA Approves First Cell-Based Therapies for Treatment of Sickle Cell Disease | Goodwin

On December 8, 2023, the FDA approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older—Vertex’s CASGEVY and Bluebird’s LYFGENIA.  SCD is a group of inherited blood disorders affecting approximately 100,000 people in the U.S. and inducing a median life…

Continue Reading FDA Approves First Cell-Based Therapies for Treatment of Sickle Cell Disease | Goodwin

Non-viral gene-editing strategy promising way to treat RDEB

A new gene-editing strategy that does not require the use of a virus can effectively correct a COL7A1 gene mutation in skin cells derived from people with recessive dystrophic epidermolysis bullosa (RDEB), according to a recent report. Most gene therapies in development require the use of viral carriers to help…

Continue Reading Non-viral gene-editing strategy promising way to treat RDEB

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development

Drug the undrugable, treat the untreatable, the revolution in drug development is happening all around us The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval,…

Continue Reading Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development

A CRISPR pioneer looks back as the first gene-editing therapy is approved

Credit: Pixabay/CC0 Public Domain In 2007, Luciano Marraffini struck out on what was then a scientifically lonely path: to understand CRISPR, which had been discovered in bacteria only about a decade before. Seventeen years later, we all know what CRISPR is: a revolution in medicine; a once-in-a-lifetime scientific breakthrough; the…

Continue Reading A CRISPR pioneer looks back as the first gene-editing therapy is approved

Sickle Cell Disease Gene Therapies Approved by FDA Highlighting Potential of CRISPR/Cas9 Technologies

In a landmark decision last week, the US Food and Drug Administration (FDA) approved two treatments involving cell-based gene therapies.  An agency within the US Department of Health and Human Services, the FDA assures the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for…

Continue Reading Sickle Cell Disease Gene Therapies Approved by FDA Highlighting Potential of CRISPR/Cas9 Technologies

Solved 6. A few years ago I set up a cross between BDSC

Transcribed image text: 6. A few years ago I set up a cross between BDSC \#79543 females and \#51324 males. Here are the relevant parts of their genotypes: #79543 = P{TKO.GS02468}attP40/CyO  [P\{TKO.GS02468\}attP40 is an inserted element on chromosome 2 that expresses an sgRNA for Cas9-mediated mutagenesis of the white gene] #51324=w; PBac {y[+ mDint2] GFP[E.3xP3]=vas-Cas9}VK00027  […

Continue Reading Solved 6. A few years ago I set up a cross between BDSC

Researchers discover first-ever link between hemoglobin-like protein and normal heart development

cygb2 mutant phenotype presents organ laterality defects. a CRISPR/Cas9 mediated genome editing of cygb2. Two different gRNA were targeted to exon 1 (denoted by red text) and resulted in 4 bp and 1 bp frame shift mutations (beginning in the blue shaded region of the predicted protein structure) named cygb2801a and cygb2801b,…

Continue Reading Researchers discover first-ever link between hemoglobin-like protein and normal heart development

Vertex-CRISPR’s Casgevy Gets Positive EMA Panel Opinion, Approval Decision in Q1 2024

Pictured: European Medicines Agency sign on building/iStock, Lubo Ivanko Following in the footsteps of U.K. and U.S. regulators, a European Medicines Agency committee on Thursday endorsed Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, which is intended for the treatment of sickle cell disease and transfusion‑dependent beta thalassemia in Europe.  EMA’s Committee…

Continue Reading Vertex-CRISPR’s Casgevy Gets Positive EMA Panel Opinion, Approval Decision in Q1 2024

First gene editing therapy to treat beta thalassemia and severe sickle cell disease

EMA has recommended approval of the first medicine using CRISPR/Cas9, a novel gene-editing technology. Casgevy (exagamglogene autotemcel) is indicated for the treatment of transfusion‑dependent beta thalassemia and severe sickle cell disease in patients 12 years of age and older for whom haematopoietic stem cell transplantation is appropriate and a suitable donor…

Continue Reading First gene editing therapy to treat beta thalassemia and severe sickle cell disease

Editas cashes in on CRISPR patent with Vertex deal

Dive Brief: Days after winning U.S. approval of the first CRISPR gene-editing medicine, Vertex Pharmaceuticals is clearing up potential intellectual property questions about the sickle cell disease therapy by signing a deal with Editas Medicine. In return for a non-exclusive license to use the gene editing technology in the treatment,…

Continue Reading Editas cashes in on CRISPR patent with Vertex deal

Tome Biosciences Raises $213M to Commercialize MIT Developed Genome Editing Tech

Methods of editing the genome are powering the development of new cell and gene therapies for diseases that have been challenging to treat. Companies like Tome Biosciences are part of a wave of startups building commercial platforms that leverage CRISPR/Cas9 and other genome editing technologies.  Earlier this week, Tome raised…

Continue Reading Tome Biosciences Raises $213M to Commercialize MIT Developed Genome Editing Tech

Gene Therapy Market Poised for Remarkable Growth with 19.6% CAGR, Reaching US$27.3 Billion by 2030

PRESS RELEASE Published December 14, 2023 The global gene therapy market is set for robust growth, with a strong compound annual growth rate (CAGR) of 19.6% projected from 2023 to 2030. This remarkable expansion is expected to drive market revenue from US$7.8 billion in 2022 to a staggering US$27.3 billion…

Continue Reading Gene Therapy Market Poised for Remarkable Growth with 19.6% CAGR, Reaching US$27.3 Billion by 2030

MD Anderson Research Highlights for December

HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at…

Continue Reading MD Anderson Research Highlights for December

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine’s cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license…

Continue Reading Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Approval of gene therapy ‘transformative’ in SCD

New regulatory decisions in the U.S. and the U.K. have made Casgevy (exagamglogene autotemcel) the first gene-editing therapy to be approved for adults and adolescents with sickle cell disease (SCD) who experience painful vaso-occlusive crises (VOCs). With these recent approvals, the therapy from Vertex Pharmaceuticals and CRISPR Therapeutics also became…

Continue Reading Approval of gene therapy ‘transformative’ in SCD

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Editas Medicine, Inc. EDIT announced entering into a licensing agreement with Vertex Pharmaceuticals VRTX for the development of the latter’s new sickle cell disease (SCD) gene therapy, Casgevy. Per the terms of the agreement, Vertex will receive a non-exclusive license to utilize Editas’ Cas9 gene editing technology for ex vivo gene editing medicines…

Continue Reading Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

RoslinCT to Manufacture CRISPR-Based Gene Therapy Casgevy

RoslinCT will manufacture Vertex Pharmaceuticals’ CRISPR-based gene therapy, Casgevy, recently approved for treating sickle cell disease and β thalassemia. On Dec. 11, 2023, RoslinCT, a UK-based cell and gene therapy contract development and manufacturing organization (CDMO), announced that it will manufacture Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel [exa-cel]), a recently approved…

Continue Reading RoslinCT to Manufacture CRISPR-Based Gene Therapy Casgevy

Growth Is Still a Better Choice

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is a leader in the global cystic fibrosis therapeutics market. In addition, the company has an extensive portfolio of experimental medicines aimed at treating common diseases such as type 1 diabetes, sickle cell anemia and APOL1-mediated kidney disease (AMKD). Investment thesis On Dec. 8, the Food…

Continue Reading Growth Is Still a Better Choice

Vertex signs $100m CRISPR deal to use sickle cell treatment

Tada Images / Shutterstock.com More on this story Other related Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines. Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists…

Continue Reading Vertex signs $100m CRISPR deal to use sickle cell treatment

STAT Health News: Medication abortion, mifepristone, pregnancy

Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. Good morning. Reproductive health is dominating the news and the newsletter this morning. We also have a look at the decade-long battle over a patent for CRISPR. It’s been a rollicking…

Continue Reading STAT Health News: Medication abortion, mifepristone, pregnancy

The latest on Moderna, Apellis, and Merck

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business. The need-to-know this morning Apellis Pharmaceuticals said a…

Continue Reading The latest on Moderna, Apellis, and Merck

Vertex licenses Editas’ gene editing technology in $100m deal

Vertex will pay $50m to Editas upfront, with an additional contingent $50m payment. Image credit: Shutterstock/Catalin Rusnac. Vertex Pharmaceuticals has entered a license agreement with Editas Medicine to use the latter company’s Cas9 gene editing technology. Vertex will pay $50m to Editas upfront, with an additional contingent $50m payment, according…

Continue Reading Vertex licenses Editas’ gene editing technology in $100m deal